NCCN GUIDELINES ® INSIGHTS CE Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024

Joyce Liu, Andrew Berchuck, Floor J. Backes, Joshua Cohen, Rachel Grisham, Charles A. Leath, Lainie Martin, Daniela Matei, David S. Miller, Sharon Robertson, Lisa Barroilhet, Shitanshu Uppal, Andrea Wahner Hendrickson, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Gottfried E. Konecny, John Moroney, Elena RatnerJohn Schorge, Premal H. Thaker, Theresa L. Werner, Emese Zsiros, Kian Behbakht, Lee May Chen, Marie DeRosa, Eric L. Eisenhauer, Gary Leiserowitz, Babak Litkouhi, Michael McHale, Sanja Percac-Lima, Kerry Rodabaugh, Roberto Vargas, Frankie Jones, Emily Kovach, Lisa Hang, Swathi Ramakrishnan, Ronald D. Alvarez, Deborah K. Armstrong

Research output: Contribution to journalArticlepeer-review

Abstract

The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.

Original languageEnglish
Pages (from-to)512-519
Number of pages8
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume22
Issue number8
DOIs
StatePublished - Oct 2024

Keywords

  • Fallopian Tube Neoplasms/diagnosis
  • Female
  • Humans
  • Medical Oncology/standards
  • Neoplasm Staging
  • Ovarian Neoplasms/diagnosis
  • Peritoneal Neoplasms/therapy
  • Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use

Fingerprint

Dive into the research topics of 'NCCN GUIDELINES ® INSIGHTS CE Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024'. Together they form a unique fingerprint.

Cite this